Lisata Therapeutics (LSTA) Enterprise Value (2016 - 2025)
Lisata Therapeutics' Enterprise Value history spans 13 years, with the latest figure at -$16.2 million for Q4 2025.
- For Q4 2025, Enterprise Value rose 1.54% year-over-year to -$16.2 million; the TTM value through Dec 2025 reached -$16.2 million, up 1.54%, while the annual FY2025 figure was -$16.2 million, 1.54% up from the prior year.
- Enterprise Value reached -$16.2 million in Q4 2025 per LSTA's latest filing, up from -$19.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$12.4 million in Q2 2025 to a low of -$32.7 million in Q3 2023.
- Average Enterprise Value over 3 years is -$20.5 million, with a median of -$19.5 million recorded in 2024.
- Peak YoY movement for Enterprise Value: fell 0.71% in 2024, then soared 48.7% in 2025.
- A 3-year view of Enterprise Value shows it stood at -$22.8 million in 2023, then rose by 27.94% to -$16.5 million in 2024, then increased by 1.54% to -$16.2 million in 2025.
- Per Business Quant, the three most recent readings for LSTA's Enterprise Value are -$16.2 million (Q4 2025), -$19.3 million (Q3 2025), and -$12.4 million (Q2 2025).